ArticleTherapeutic advances in medical oncology2022
Cost-effectiveness of ribociclib for premenopausal or perimenopausal women with HR+/HER2- advanced breast cancer: a Brazilian public health care system perspective.
Daniela Dornelles Rosa et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.